<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.0 20040830//EN" "journalpublishing.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="2.0" xml:lang="en" article-type="letter"><front><journal-meta><journal-id journal-id-type="nlm-ta">JMIR Dermatol</journal-id><journal-id journal-id-type="publisher-id">derma</journal-id><journal-id journal-id-type="index">29</journal-id><journal-title>JMIR Dermatology</journal-title><abbrev-journal-title>JMIR Dermatol</abbrev-journal-title><issn pub-type="epub">2562-0959</issn><publisher><publisher-name>JMIR Publications</publisher-name><publisher-loc>Toronto, Canada</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">v8i1e70067</article-id><article-id pub-id-type="doi">10.2196/70067</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Letter</subject></subj-group></article-categories><title-group><article-title>Popular Treatments of Psoriasis on Social Media: Google Trends Analysis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Nguyen</surname><given-names>Derek</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Javaheri</surname><given-names>Jennifer</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sanchez</surname><given-names>Ruth</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Han</surname><given-names>Vy</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><institution>Psychology Department, University of California, Riverside</institution><addr-line>900 University Ave</addr-line><addr-line>Riverside</addr-line><addr-line>CA</addr-line><country>United States</country></aff><aff id="aff2"><institution>California University of Science and Medicine</institution><addr-line>Colton</addr-line><addr-line>CA</addr-line><country>United States</country></aff><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Guo</surname><given-names>William</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name name-style="western"><surname>Gulati</surname><given-names>Nicholas</given-names></name></contrib><contrib contrib-type="reviewer"><name name-style="western"><surname>Tan</surname><given-names>Qinyi</given-names></name></contrib></contrib-group><author-notes><corresp>Correspondence to Derek Nguyen, Psychology Department, University of California, Riverside, 900 University Ave, Riverside, CA, 92521, United States, 1 7148802250; <email>derekn1099@gmail.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>28</day><month>3</month><year>2025</year></pub-date><volume>8</volume><elocation-id>e70067</elocation-id><history><date date-type="received"><day>14</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>28</day><month>02</month><year>2025</year></date><date date-type="accepted"><day>06</day><month>03</month><year>2025</year></date></history><copyright-statement>&#x00A9; Derek Nguyen, Jennifer Javaheri, Ruth Sanchez, Vy Han. Originally published in JMIR Dermatology (<ext-link ext-link-type="uri" xlink:href="http://derma.jmir.org">http://derma.jmir.org</ext-link>), 28.3.2025. </copyright-statement><copyright-year>2025</copyright-year><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Dermatology, is properly cited. The complete bibliographic information, a link to the original publication on <ext-link ext-link-type="uri" xlink:href="http://derma.jmir.org">http://derma.jmir.org</ext-link>, as well as this copyright and license information must be included.</p></license><self-uri xlink:type="simple" xlink:href="https://derma.jmir.org/2025/1/e70067"/><abstract><p>This study analyzes the most commonly mentioned psoriasis treatments on Facebook and Reddit forums, tracking their popularity over time by using Google Trends.</p></abstract><kwd-group><kwd>psoriasis</kwd><kwd>biologics</kwd><kwd>Google Trends</kwd><kwd>Reddit</kwd><kwd>Facebook</kwd><kwd>treatment</kwd></kwd-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Approximately 8 million individuals in the United States and 125 million individuals worldwide experience psoriasis&#x2014;a chronic inflammatory skin disease most commonly characterized by scaly erythematous plaques on the extensor surfaces, face, trunk, and scalp. With increased internet accessibility, many patients now turn to web-based platforms to connect with others and seek advice on managing their condition. Over 30% of internet users report using social media to find health-related information, with forums and web-based communities being among the most popular sources [<xref ref-type="bibr" rid="ref1">1</xref>]. Notably, two widely used resources in the psoriasis community are the &#x201C;Psoriasis&#x201D; group on Facebook and &#x201C;r/Psoriasis&#x201D; on Reddit, which collectively have over 110,000 users worldwide. We aimed to analyze the most frequently mentioned treatments on these forums while also exploring how interest has evolved over time. By comparing patient discussions with search trends, this research provides valuable insights into treatment preferences and shifts in public awareness.</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><p>Using the web application PullPush API&#x2014;an indexing service that enables users to retrieve content beyond Reddit&#x2019;s 1000-entry search limit&#x2014;all posts on both web-based forums from May 23 to November 23, 2024, were compiled and reviewed to assess their relevance to psoriasis treatment, before tallying the number of mentions each unique treatment received. Non-English posts were excluded from data collection due to their small sample size and practical limitations. The 10 most mentioned treatments across both forums were inputted into Google Trends to assess their popularity over time. These treatments were further categorized into groups&#x2014;disease-modifying antirheumatic drugs (DMARDs), steroids, and procedures. Google Trends allows users to track the popularity of queries by displaying search interest for queries as relative search volumes (RSVs). RSVs range from 1 to 100, where the number indicates how a topic&#x2019;s search interest compares to its peak interest level. To convert this value to the total number of searches at any given time, the Google Chrome extension Glimpse was used to convert all RSVs to absolute search volumes.</p></sec><sec id="s3" sec-type="results"><title>Results</title><p>The gathered posts contained 2260 unique mentions of treatments, which were categorized into 205 unique treatments. Treatments fell under the following categories: biologics, procedures, dietary modifications, home remedies, and topicals. The 10 most mentioned treatments across both forums are shown in <xref ref-type="table" rid="table1">Table 1</xref>. Of these, 2 did not meet the minimum search queries necessary to generate graphical data through Google Trends. Among the remaining treatments, those with the highest number of searches in any month between 2008 and 2024 were methotrexate, with 13,860 searches in January 2010, and Humira, with 14,396 searches in February 2009 (<xref ref-type="fig" rid="figure1">Figure 1</xref>). These results could be explained by shortages in methotrexate and other oncology drugs between 2010 and 2011 and the US Food and Drug Administration&#x2019;s approval of Humira for plaque psoriasis in 2008, respectively [<xref ref-type="bibr" rid="ref2">2</xref>]. In recent years however, Humira has experienced declines in popularity due to the availability of cheaper biosimilars [<xref ref-type="bibr" rid="ref3">3</xref>]. UV-B phototherapy has likewise experienced a similar trend due to the increase in biologics use [<xref ref-type="bibr" rid="ref4">4</xref>]. Overall, the subcategories that displayed the highest interest based on the daily number of searches were biologic DMARDs (searches: n=768), steroids (searches: n=93), and procedures (searches: n=151).</p><table-wrap id="t1" position="float"><label>Table 1.</label><caption><p>Most mentioned treatments<sup><xref ref-type="table-fn" rid="table1fn1">a</xref></sup> for psoriasis across Facebook and Reddit in 2024.</p></caption><table id="table1" frame="hsides" rules="groups"><thead><tr><td align="left" valign="top">Treatment</td><td align="left" valign="top">Mentions (N=2260), n (%)</td></tr></thead><tbody><tr><td align="left" valign="top">Risankizumab<sup><xref ref-type="table-fn" rid="table1fn2">b</xref></sup></td><td align="left" valign="top">181 (8)</td></tr><tr><td align="left" valign="top">UV-B phototherapy<sup><xref ref-type="table-fn" rid="table1fn3">c</xref></sup></td><td align="left" valign="top">129 (5.7)</td></tr><tr><td align="left" valign="top">Apremilast<sup><xref ref-type="table-fn" rid="table1fn2">b</xref></sup></td><td align="left" valign="top">103 (4.6)</td></tr><tr><td align="left" valign="top">Methotrexate<sup><xref ref-type="table-fn" rid="table1fn2">b</xref></sup></td><td align="left" valign="top">102 (4.5)</td></tr><tr><td align="left" valign="top">Adalimumab<sup><xref ref-type="table-fn" rid="table1fn2">b</xref></sup></td><td align="left" valign="top">97 (4.3)</td></tr><tr><td align="left" valign="top">Guselkumab<sup><xref ref-type="table-fn" rid="table1fn2">b</xref></sup></td><td align="left" valign="top">81 (3.6)</td></tr><tr><td align="left" valign="top">Secukinumab<sup><xref ref-type="table-fn" rid="table1fn2">b</xref></sup></td><td align="left" valign="top">72 (3.2)</td></tr><tr><td align="left" valign="top">Clobetasol propionate<sup><xref ref-type="table-fn" rid="table1fn4">d</xref></sup></td><td align="left" valign="top">70 (3.1)</td></tr><tr><td align="left" valign="top">Cal/BD<sup><xref ref-type="table-fn" rid="table1fn5">e</xref></sup> foam<sup><xref ref-type="table-fn" rid="table1fn4">d</xref></sup></td><td align="left" valign="top">68 (3)</td></tr><tr><td align="left" valign="top">Ixekizumab<sup><xref ref-type="table-fn" rid="table1fn2">b</xref></sup></td><td align="left" valign="top">50 (2.2)</td></tr><tr><td align="left" valign="top">Remaining 195 treatments</td><td align="left" valign="top">1307 (57.8)</td></tr></tbody></table><table-wrap-foot><fn id="table1fn1"><p><sup>a</sup>In total, there were 205 unique treatments mentioned.</p></fn><fn id="table1fn2"><p><sup>b</sup>Categorized as a disease-modifying antirheumatic drug.</p></fn><fn id="table1fn3"><p><sup>c</sup>Categorized as a procedure.</p></fn><fn id="table1fn4"><p><sup>d</sup>Categorized as a steroid.</p></fn><fn id="table1fn5"><p><sup>e</sup>Cal/BD: calcipotriol/betamethasone dipropionate.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="figure1"><label>Figure 1.</label><caption><p>ASV data from Google Trends for the 10 most discussed psoriasis treatments on Reddit and Facebook (2008&#x2010;2024). ASV: absolute search volume; DMARD: disease-modifying antirheumatic drug.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="derma_v8i1e70067_fig01.png"/></fig></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>Google Trends data reveal that patients prefer injectable medications, especially biologics, for treating psoriasis, with 5 of the top 10 treatments falling into this category. This trend aligns with previous research highlighting patients&#x2019; appreciation for the efficiency and convenience of biologics [<xref ref-type="bibr" rid="ref5">5</xref>]. However, given past research indicating an increased risk of developing cutaneous disorders, inflammatory bowel disease, or interstitial lung disease, patients should be informed about alternative treatment options [<xref ref-type="bibr" rid="ref6">6</xref>]. This study&#x2019;s limitations include the exclusion of other social media platforms and potential selection bias, as social media use tends to be more prevalent among younger demographics [<xref ref-type="bibr" rid="ref7">7</xref>].</p><p>Due to the significant disease burden associated with psoriasis, many patients seek additional treatment options, of which some lack strong evidence. Notably, 51% of patients report using complementary and alternative medicine (CAM), including herbal therapy, climatotherapy, and dietary changes, with many forum users recommending dairy-free or gluten-free diets. Common reasons for these choices include preferences for natural approaches, cultural factors, and a perception that conventional medicine is more toxic than CAM treatments [<xref ref-type="bibr" rid="ref8">8</xref>,<xref ref-type="bibr" rid="ref9">9</xref>]. Given their rising popularity, understanding the data surrounding the efficacy of these treatments and their interactions with conventional medicine will better equip dermatologists to serve patients. Interest in psoriasis treatments should center on expanding the evidence base for conventional and alternative treatments and fostering effective collaboration between patients and physicians to optimize outcomes.</p></sec></body><back><fn-group><fn fn-type="conflict"><p>None declared.</p></fn></fn-group><glossary><title>Abbreviations</title><def-list><def-item><term id="abb1">CAM</term><def><p>complementary and alternative medicine</p></def></def-item><def-item><term id="abb2">DMARD</term><def><p>disease-modifying antirheumatic drug</p></def></def-item><def-item><term id="abb3">RSV</term><def><p>relative search volume</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><label>1</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tulbert</surname><given-names>BH</given-names> </name><name name-style="western"><surname>Snyder</surname><given-names>CW</given-names> </name><name name-style="western"><surname>Brodell</surname><given-names>RT</given-names> </name></person-group><article-title>Readability of patient-oriented online dermatology resources</article-title><source>J Clin Aesthet Dermatol</source><year>2011</year><month>03</month><volume>4</volume><issue>3</issue><fpage>27</fpage><lpage>33</lpage><pub-id pub-id-type="medline">21464884</pub-id></nlm-citation></ref><ref id="ref2"><label>2</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coghlan</surname><given-names>J</given-names> </name><name name-style="western"><surname>He</surname><given-names>H</given-names> </name><name name-style="western"><surname>Schwendeman</surname><given-names>AS</given-names> </name></person-group><article-title>Overview of Humira&#x00AE; biosimilars: current European landscape and future implications</article-title><source>J Pharm Sci</source><year>2021</year><month>04</month><volume>110</volume><issue>4</issue><fpage>1572</fpage><lpage>1582</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2021.02.003</pub-id><pub-id pub-id-type="medline">33556387</pub-id></nlm-citation></ref><ref id="ref3"><label>3</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Becker</surname><given-names>DJ</given-names> </name><name name-style="western"><surname>Talwar</surname><given-names>S</given-names> </name><name name-style="western"><surname>Levy</surname><given-names>BP</given-names> </name><etal/></person-group><article-title>Impact of oncology drug shortages on patient therapy: unplanned treatment changes</article-title><source>J Oncol Pract</source><year>2013</year><month>07</month><volume>9</volume><issue>4</issue><fpage>e122</fpage><lpage>e128</lpage><pub-id pub-id-type="doi">10.1200/JOP.2012.000799</pub-id><pub-id pub-id-type="medline">23942928</pub-id></nlm-citation></ref><ref id="ref4"><label>4</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torres</surname><given-names>AE</given-names> </name><name name-style="western"><surname>Lyons</surname><given-names>AB</given-names> </name><name name-style="western"><surname>Hamzavi</surname><given-names>IH</given-names> </name><name name-style="western"><surname>Lim</surname><given-names>HW</given-names> </name></person-group><article-title>Role of phototherapy in the era of biologics</article-title><source>J Am Acad Dermatol</source><year>2021</year><month>02</month><volume>84</volume><issue>2</issue><fpage>479</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2020.04.095</pub-id><pub-id pub-id-type="medline">32339702</pub-id></nlm-citation></ref><ref id="ref5"><label>5</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Florek</surname><given-names>AG</given-names> </name><name name-style="western"><surname>Wang</surname><given-names>CJ</given-names> </name><name name-style="western"><surname>Armstrong</surname><given-names>AW</given-names> </name></person-group><article-title>Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review</article-title><source>Arch Dermatol Res</source><year>2018</year><month>05</month><volume>310</volume><issue>4</issue><fpage>271</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1007/s00403-018-1808-x</pub-id><pub-id pub-id-type="medline">29442137</pub-id></nlm-citation></ref><ref id="ref6"><label>6</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ion</surname><given-names>A</given-names> </name><name name-style="western"><surname>Doroban&#x021B;u</surname><given-names>AM</given-names> </name><name name-style="western"><surname>Popa</surname><given-names>LG</given-names> </name><name name-style="western"><surname>Mihai</surname><given-names>MM</given-names> </name><name name-style="western"><surname>Orzan</surname><given-names>OA</given-names> </name></person-group><article-title>Risks of biologic therapy and the importance of multidisciplinary approach for an accurate management of patients with moderate-severe psoriasis and concomitant diseases</article-title><source>Biology (Basel)</source><year>2022</year><month>05</month><day>25</day><volume>11</volume><issue>6</issue><fpage>808</fpage><pub-id pub-id-type="doi">10.3390/biology11060808</pub-id><pub-id pub-id-type="medline">35741329</pub-id></nlm-citation></ref><ref id="ref7"><label>7</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shabir</surname><given-names>G</given-names> </name><name name-style="western"><surname>Iqbal</surname><given-names>YW</given-names> </name><name name-style="western"><surname>Safdar</surname><given-names>G</given-names> </name></person-group><article-title>Demographics&#x2019; differences in social networking sites use: what communication motives does it gratify?</article-title><source>International Journal of Social Work and Human Services Practice</source><year>2014</year><volume>2</volume><issue>5</issue><fpage>184</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.13189/ijrh.2014.020503</pub-id></nlm-citation></ref><ref id="ref8"><label>8</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gamret</surname><given-names>AC</given-names> </name><name name-style="western"><surname>Price</surname><given-names>A</given-names> </name><name name-style="western"><surname>Fertig</surname><given-names>RM</given-names> </name><name name-style="western"><surname>Lev-Tov</surname><given-names>H</given-names> </name><name name-style="western"><surname>Nichols</surname><given-names>AJ</given-names> </name></person-group><article-title>Complementary and alternative medicine therapies for psoriasis: a systematic review</article-title><source>JAMA Dermatol</source><year>2018</year><month>11</month><day>1</day><volume>154</volume><issue>11</issue><fpage>1330</fpage><lpage>1337</lpage><pub-id pub-id-type="doi">10.1001/jamadermatol.2018.2972</pub-id><pub-id pub-id-type="medline">30193251</pub-id></nlm-citation></ref><ref id="ref9"><label>9</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magin</surname><given-names>PJ</given-names> </name><name name-style="western"><surname>Adams</surname><given-names>J</given-names> </name><name name-style="western"><surname>Heading</surname><given-names>GS</given-names> </name><name name-style="western"><surname>Pond</surname><given-names>DC</given-names> </name><name name-style="western"><surname>Smith</surname><given-names>W</given-names> </name></person-group><article-title>Complementary and alternative medicine therapies in acne, psoriasis, and atopic eczema: results of a qualitative study of patients&#x2019; experiences and perceptions</article-title><source>J Altern Complement Med</source><year>2006</year><month>06</month><volume>12</volume><issue>5</issue><fpage>451</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1089/acm.2006.12.451</pub-id><pub-id pub-id-type="medline">16813509</pub-id></nlm-citation></ref></ref-list></back></article>